CytoDyn's wholly owned subsidiary, Advanced Genetic Technologies, holds the exclusive worldwide licenses for monoclonal antibodies TS1-18 and TS1-22, and the non-exclusive rights to the bacterial plasmid 8630. TS1-18, is specific for the human CD18 antigen and TS1-22 is specific for the CD11a antigen. Together, the CD18 and CD11a antigens make up the adhesion molecule LFA-1, a documented potential target for HIV infection. The bacterial plasmid 8630 encodes for the complete sequence of the human CD11a gene. These antibodies and plasmid were developed by Dr. Timothy Springer, a senior investigator at the CBR institute for Biomedical Research, an affiliate of Harvard Medical School. CytoDyn intends to explore the use of TS1-22 and TS1-18 antibodies as second generation therapeutics for HIV and FIV.
CytoDyn's wholly owned subsidiary, CytoDyn Veterinary Medicine, was created to develop and advance CytoDyn's strategic selective diversification of antibodies for the treatment FIV in cats, and of other infectious diseases in animals. CytoDyn will also continue to pursue additional potential specific antibody applications for use in animals.
